Seed companies and public-funded farm research bodies have invested heavily in GM research. Prolongation of the moratorium would have rendered these investments unproductive, thereby forcing many companies - at least the multinationals - to shift their research and development base outside India. The ill-effects of hampering GM research are apparent. India, already a late starter in this field, has been left further behind developed and even some fast-growing countries, such as China and Brazil, in tapping potential gains from biotechnology in various fields, including agriculture and pharmaceuticals.
Certainly, concerns over bio-safety aspects of GM products, especially transgenic crops where genes from alien, non-plant sources have been inserted into them, should not be overlooked. These can be addressed by suitably amending the GM regulatory regime, which, in its present incarnation, lacks autonomy. Its credibility, too, has been eroded by shifting the powers of final approval of GM crops from the GEAC to the environment ministry. A recent paper published in the February 2014 issue of Plant Biotechnology Journal points out some inherent flaws in the legal regime governing the GM sector. For some odd reasons, the GM crops have been listed among the hazardous substances under the Environment Protection Act, 1986. This is scientifically untenable. Besides, there is a dichotomy regarding GM crops between the powers of the Centre and those of the states. While the Union environment ministry has the power to regulate and approve GM crops, the right to allow or disallow the experimentation and cultivation of such crops in open fields rests with state governments - since agriculture is a state subject. This often leads to Centre-state conflicts in decision making. Sadly, an updated and sensible regulatory Bill was introduced but not passed by this Parliament.
There is, therefore, an urgent need to either thoroughly revamp the current regulatory framework or, preferably, replace it with a new one that is immune to political interventions or external pressures. However, trials of GM crops should no longer be blocked, for that would be a disservice to farmers and consumers.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
